v3.26.3
Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Product Information [Line Items]      
Accounts receivable, net $ 1,218,000   $ 2,254,000
Reserve for credit losses 974,000   1,014,000
Allowance for loans losses 7,451,000   7,478,000
Inventory, allowance for obsolescence 134,000   53,000
Goodwill $ 1,769,000   1,769,000
Antidilutive securities 36,444,000 0  
Cash $ 3,300,000    
Working capital 42,800,000    
Sale of marketable securities $ 600,000    
Impact BioMedical, Inc. [Member]      
Product Information [Line Items]      
Goodwill     $ 1,769,000
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage 28.00% 25.00%  
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage 14.00% 36.00% 19.00%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage 14.00% 10.00% 18.00%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage     13.00%
Customer Four [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage     12.00%
Customer Five [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk percentage     11.00%